The three double-arm trials included in this study compared the pCR in HER2-positive breast cancer patients after being treated with chemotherapy (C) + trastuzumab (T) + pertuzumab (P) vs. chemotherapy (C) + trastuzumab (T). This evidence concerns the gene ERBB2 and breast carcinoma.